Abstract
Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy. Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination. Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters. Results: Across 2769 COVID-19–vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination–induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination–induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine–related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions. Conclusions: COVID-19 vaccination leads to disease exacerbation in only a small number of CU patients and is generally well tolerated.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Allergy and Clinical Immunology |
| Vol/bind | 152 |
| Udgave nummer | 5 |
| Sider (fra-til) | 1095-1106 |
| ISSN | 0091-6749 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Publisher Copyright:© 2023 American Academy of Allergy, Asthma & Immunology
Adgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination : Results of the UCARE COVAC-CU study. / Kocatürk, Emek; Salameh, Pascale; Sarac, Esra; Vera Ayala, Carolina E.; Thomsen, Simon Francis; Zuberbier, Torsten; Ensina, Luis Felipe; Popov, Todor A.; van Doorn, Martijn B.A.; Giménez-Arnau, Ana Maria; Asero, Riccardo; Criado, Paulo Ricardo; Aarestrup, Fernando M.; AbdulHameed Ansari, Zainab; Al Abri, Salma; Al Ahmad, Mona; Al Hinai, Bushra; Allenova, Anastasiia; Al-Nesf, Maryam; Altrichter, Sabine; Arnaout, Rand; Bartosińska, Joanna; Bauer, Andrea; Bernstein, Jonathan A.; Bizjak, Mojca; Bonnekoh, Hanna; Bouillet, Laurence; Brzoza, Zenon; Calvalcanti Dela Bianca Melo, Ana Caroline; Campinhos, Fernanda L.; Carne, Emily; Purayil, Saleema Cherichi; Cherrez-Ojeda, Ivan; Chong-Neto, Herberto Jose; Christoff, George; Conlon, Niall; Jardim Criado, Roberta Fachini; Cvenkel, Klara; Damadoglu, Ebru; Danilycheva, Inna; Day, Cascia; de Montjoye, Laurence; Demir, Semra; Ferucci, Silvia Mariel; Fomina, Daria; Fukunaga, Atsushi; Garcia, Elizabeth; Gelincik, Asli; Göbel, Joe Hannah; Godse, Kiran; Gonçalo, Margarida; Gotua, Maia; Grattan, Clive; Gugala, Agata; Guillet, Carole; Kalyoncu, Ali Fuat; Karakaya, Gul; Kasperska-Zając, Alicja; Katelaris, Constance H.; Khoshkhui, Maryam; Kleinheinz, Andreas; Kolacinska-Flont, Marta; Kolkhir, Pavel; Košnik, Mitja; Krasowska, Dorota; Kumaran, Muthu Sendhil; Kuprys-Lipinska, Izabela; Kurowski, Marcin; Kuznetsova, Elizaveta V.; Larenas-Linnemann, Désirée; Lebedkina, Marina S.; Lee, Youngsoo; Makris, Michael P.; Gómez, René Maximiliano; Nasr, Iman; Neisinger, Sophia; Oda, Yoshiko; Kara, Rabia Öztaş; Palitot, Esther Bastos; Papapostolou, Niki; Salvador Parisi, Claudio Alberto; Pesque, David; Peter, Jonathan; Petkova, Elena; Ridge, Katie; Rudenko, Michael; Rutkowski, Krzysztof; Saini, Sarbjit S.; Salman, Andac; Sanchez, Jorge; Şekerel, Bülent; Serdotetskova, Sofia A.; Serpa, Faradiba S.; Dikicier, Bahar Sevimli; Sidiropoulos, Nikitas; Sikora, Agnieszka; Sørensen, Jennifer Astrup; Soria, Angele; Kucuk, Ozlem Su; Thalappil, Sherin Rahim; Tomaszewska, Katarzyna; Tuncay, Gulseren; Unal, Derya; Valle, Solange; van Lindonk, Esmee; Vestergaard, Christian; Vitchuk, Aleksandr; Xepapadaki, Paraskevi; Ye, Young Min; Zalewska-Janowska, Anna; Zamlynski, Mateusz; Maurer, Marcus.
I: Journal of Allergy and Clinical Immunology, Bind 152, Nr. 5, 2023, s. 1095-1106.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination
T2 - Results of the UCARE COVAC-CU study
AU - Kocatürk, Emek
AU - Salameh, Pascale
AU - Sarac, Esra
AU - Vera Ayala, Carolina E.
AU - Thomsen, Simon Francis
AU - Zuberbier, Torsten
AU - Ensina, Luis Felipe
AU - Popov, Todor A.
AU - van Doorn, Martijn B.A.
AU - Giménez-Arnau, Ana Maria
AU - Asero, Riccardo
AU - Criado, Paulo Ricardo
AU - Aarestrup, Fernando M.
AU - AbdulHameed Ansari, Zainab
AU - Al Abri, Salma
AU - Al Ahmad, Mona
AU - Al Hinai, Bushra
AU - Allenova, Anastasiia
AU - Al-Nesf, Maryam
AU - Altrichter, Sabine
AU - Arnaout, Rand
AU - Bartosińska, Joanna
AU - Bauer, Andrea
AU - Bernstein, Jonathan A.
AU - Bizjak, Mojca
AU - Bonnekoh, Hanna
AU - Bouillet, Laurence
AU - Brzoza, Zenon
AU - Calvalcanti Dela Bianca Melo, Ana Caroline
AU - Campinhos, Fernanda L.
AU - Carne, Emily
AU - Purayil, Saleema Cherichi
AU - Cherrez-Ojeda, Ivan
AU - Chong-Neto, Herberto Jose
AU - Christoff, George
AU - Conlon, Niall
AU - Jardim Criado, Roberta Fachini
AU - Cvenkel, Klara
AU - Damadoglu, Ebru
AU - Danilycheva, Inna
AU - Day, Cascia
AU - de Montjoye, Laurence
AU - Demir, Semra
AU - Ferucci, Silvia Mariel
AU - Fomina, Daria
AU - Fukunaga, Atsushi
AU - Garcia, Elizabeth
AU - Gelincik, Asli
AU - Göbel, Joe Hannah
AU - Godse, Kiran
AU - Gonçalo, Margarida
AU - Gotua, Maia
AU - Grattan, Clive
AU - Gugala, Agata
AU - Guillet, Carole
AU - Kalyoncu, Ali Fuat
AU - Karakaya, Gul
AU - Kasperska-Zając, Alicja
AU - Katelaris, Constance H.
AU - Khoshkhui, Maryam
AU - Kleinheinz, Andreas
AU - Kolacinska-Flont, Marta
AU - Kolkhir, Pavel
AU - Košnik, Mitja
AU - Krasowska, Dorota
AU - Kumaran, Muthu Sendhil
AU - Kuprys-Lipinska, Izabela
AU - Kurowski, Marcin
AU - Kuznetsova, Elizaveta V.
AU - Larenas-Linnemann, Désirée
AU - Lebedkina, Marina S.
AU - Lee, Youngsoo
AU - Makris, Michael P.
AU - Gómez, René Maximiliano
AU - Nasr, Iman
AU - Neisinger, Sophia
AU - Oda, Yoshiko
AU - Kara, Rabia Öztaş
AU - Palitot, Esther Bastos
AU - Papapostolou, Niki
AU - Salvador Parisi, Claudio Alberto
AU - Pesque, David
AU - Peter, Jonathan
AU - Petkova, Elena
AU - Ridge, Katie
AU - Rudenko, Michael
AU - Rutkowski, Krzysztof
AU - Saini, Sarbjit S.
AU - Salman, Andac
AU - Sanchez, Jorge
AU - Şekerel, Bülent
AU - Serdotetskova, Sofia A.
AU - Serpa, Faradiba S.
AU - Dikicier, Bahar Sevimli
AU - Sidiropoulos, Nikitas
AU - Sikora, Agnieszka
AU - Sørensen, Jennifer Astrup
AU - Soria, Angele
AU - Kucuk, Ozlem Su
AU - Thalappil, Sherin Rahim
AU - Tomaszewska, Katarzyna
AU - Tuncay, Gulseren
AU - Unal, Derya
AU - Valle, Solange
AU - van Lindonk, Esmee
AU - Vestergaard, Christian
AU - Vitchuk, Aleksandr
AU - Xepapadaki, Paraskevi
AU - Ye, Young Min
AU - Zalewska-Janowska, Anna
AU - Zamlynski, Mateusz
AU - Maurer, Marcus
N1 - Publisher Copyright: © 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023
Y1 - 2023
N2 - Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy. Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination. Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters. Results: Across 2769 COVID-19–vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination–induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination–induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine–related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions. Conclusions: COVID-19 vaccination leads to disease exacerbation in only a small number of CU patients and is generally well tolerated.
AB - Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy. Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination. Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters. Results: Across 2769 COVID-19–vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination–induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination–induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine–related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions. Conclusions: COVID-19 vaccination leads to disease exacerbation in only a small number of CU patients and is generally well tolerated.
KW - Adverse effects
KW - COVID-19
KW - exacerbation
KW - omalizumab
KW - real life
KW - treatment
KW - urticaria
KW - vaccination
KW - vaccine
KW - worsening
U2 - 10.1016/j.jaci.2023.07.019
DO - 10.1016/j.jaci.2023.07.019
M3 - Journal article
C2 - 37574079
AN - SCOPUS:85171640167
VL - 152
SP - 1095
EP - 1106
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 5
ER -